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Abstract
Background: The aims of this study were to characterize clinical features of a pediatric African-American cystic
fibrosis (CF) patient heterozygous for F508del and a novel c.3623G > A mutation, and to identify the molecular
defect(s) associated with c.3623G > A mutation.
Methods: The medical record of this patient was analyzed retrospectively. Western blotting and iodide efflux assay
were used to study mutant CFTR protein expression level, maturation status, channel function, and the effects of
CFTR modulation on these characteristics.
Results: The encoding protein of c.3623G > A mutation, G1208D-CFTR, has a moderate processing defect and
exhibits impaired channel function, which were partially rescued by using VX-809 or exposed to low temperature
(28 °C). The patient has mild CF disease manifestations.
Conclusions: Our biochemical findings correlate with the clinical phenotype and suggest that c.3623G > A is a
CF-causing mutation. The study helps expand our knowledge of rare CFTR mutations in a minority population
and may have important clinical implications for personalized therapeutic intervention.
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Background
Cystic fibrosis (CF) is an autosomal recessive genetic dis-
ease caused by the loss or dysfunction of the CF trans-
membrane conductance regulator (CFTR) channel activity
resulting from mutations [1, 2]. Clinically, chronic lung
disease is the main cause of morbidity and mortality for
CF patients. Other symptoms include pancreatic insuffi-
ciency, elevated sweat electrolytes, gastrointestinal disor-
ders, reproductive abnormalities, etc. [3, 4].
CFTR is a cAMP/cGMP-regulated chloride /bicarbon-
ate channel primarily expressed at the apical membrane
of epithelial cells lining airway, gut, and exocrine glands,
where it is responsible for transepithelial fluid secretion
and homeostasis [5–7]. CFTR channel function is deter-
mined by the number of channels at the cell surface, the
open probability of the channels, and the single channel
conductance. Mutations in the CFTR gene alter one or
more of these parameters, causing the impairment or
loss of the channel activity. More than 2000 CFTR mu-
tations have been identified, which can be roughly cate-
gorized into 5 groups based on the nature of defect(s)
[8]. The classification of CFTR mutations helps define
strategies to restore CFTR channel function based on
mutation-specific defect(s). It should be noted that some
mutations have multiple defects. For example, F508del,
the most prevalent CFTR mutation, induces a matur-
ation defect in CFTR protein; when this maturation de-
fect is rescued, the mutant protein still exhibits defects
in channel gating and stability at the cell surface. Among
the 2000 plus known CFTR mutations, only a relatively
few have been studied in detail both at the molecular
level and for the specific disease manifestations. In order
to better understand the disease of CF and develop ef-
fective therapies, there is a need to study the molecular
characteristics of rare CFTR mutations to identify the
defect(s), particularly for rare mutations seen in minority
populations such as African-Americans.
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In addition to therapies targeting the downstream dis-
ease consequences (symptoms), recent advancements to
target the mutant CFTR proteins (CFTR modulation)
have potentially revolutionized CF care. Kalydeco™ (also
known as ivacaftor or VX-770) was approved by U.S.
Food and Drug Administration (FDA) to treat CF pa-
tients age 2 or older with G551D and other nine class III
and IV mutations [9]. More recently, FDA approved
Orkambi™ (a combination of ivacaftor and lumacaftor
(also known as VX-809)) to treat CF patients age 12 or
older with two copies of F508del [9].
Here, we present a clinical case of a pediatric African-
American CF patient who is heterogeneous for F508del
and a novel missense mutation, c.3623G > A. The patient
had mild disease manifestations. Search in the available
databases [10–12] did not yield any information on this
mutation. The goals of this study were to characterize
this novel mutation at the molecular level to identify the
nature of defect(s), and to explore the possibility of using
mutation-specific therapy for potential interventions.
Methods
Patient characteristics
This individual received standard care at The University
of Tennessee Cystic Fibrosis Research and Care Center
at LeBonheur Children’s Hospital (Memphis, TN, USA).
The medical record was analyzed retrospectively after
expedited IRB approval (UTHSC 13-02779-XM).
Genotyping was performed at Ambry Genetics (Aliso
Viejo, CA, USA) that showed F508del mutation on one
chromosome and c.3623G > A on the other.
Diagnostic sweat chloride testing was performed on
the patient by using pilocarpine iontophoresis for dupli-
cate samples from right to left arms. Collection was per-
formed using the filter paper method according to CF
Foundation/NCCLS guidelines [13]. The chloride con-
centrations were measured by using a digital chlorid-
ometer (Labconco, Kansas City, MO, USA) with a
minimal sweat weight of 75 mg.
Antibodies and reagents
Antibodies were purchased from the following compan-
ies: Anti-CFTR, clone MM13-4 (EMD Millipore Corpor-
ation, CA, USA), anti-β-Actin (Sigma, MO, USA). VX-
809 was purchased from Selleckchem (TX, USA). Other
reagents used were purchased either from Sigma or
Fisher Scientific (PA, USA) at their highest possible
purity.
Site-directed mutagenesis
pcDNA3.1-wild type (WT)-CFTR was used to generate
c.3623G > A point mutation by using site-directed muta-
genesis (Quickchange site-directed mutagenesis kit,
Stratagene, La Jolla, CA). The primers used are:
Forward: 5′CTGGCCCTCAGGGGACCAAATGACT




All sequences were confirmed at the Molecular Re-
source Center at The University of Tennessee Health
Science Center.
Cell culture and transfection
HEK293 cells were used to express WT and mutant
CFTRs. The cells were cultured in DMEM/F12(1:1) (Invi-
trogen, Grand Island, NY, USA) medium supplemented
with 1 % penicillin-streptomycin (Invitrogen) and 10 %
Fetal bovine serum (Invitrogen) at 37 °C in 5 % CO2 incu-
bator unless otherwise stated. Lipofectamine 2000 (Invi-
trogen) was used to transfect the cells following the
instruction provided by the manufacturer. At 48 h post-
transfection, the cells were used for western blotting or
iodide efflux assay.
Western blotting
Cells were lysed in lysis buffer (1× PBS, containing 0.2 %
Triton-X-100 and protease inhibitors phenylmethylsulfo-
nyl fluoride (1 mM), pepstatin A (1 μg/ml), leupeptin
(1 μg/ml), aprotinin (1 μg/ml)) for 30 min at 4 °C. The
lysates were centrifuged at 12,000 rpm for 15 min at 4 °C.
The clear supernatants (the total protein levels were mea-
sured by using Bradford protein assay) were mixed with
4× sample buffer, denatured, subjected to SDS-PAGE on
5–14 % Gel (Bio-rad, Hercules, CA, USA), and transferred
to PVDF membranes. The membranes were blocked with
5 % milk (in 0.1 % PBS-T) and then probed for CFTR
(1:1,000 dilution) and β-actin (the loading control, 1:5,000
dilution) using the respective antibodies. The protein
bands were detected using ECL™ Western blot detection
reagents (GE Healthcare, Buckinghamshire, UK). The
densities of bands were quantified using Image J software.
Real-time PCR to measure CFTR mRNA levels
Total RNA was isolated from HEK293 cells transfected
with WT-CFTR or G1208D-CFTR or vector using Pure-
link RNA Mini Kit (Thermo Fisher, Waltham, MA,
USA). One microgram of total RNA was reversed to
cDNA using SuperScript III Reverse Transcriptase (Invi-
trogen). Real-Time PCR was performed using LightCy-




The primers for human GAPDH were:
Forward: 5′TGATGACATCAAGAAGGTGG3′
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Reverse: 5′TCGTTGTCATACCAGGAAATG3′
The PCR thermocycling parameters were: 95 °C for
5 min, and 40 cycles of 95 °C for 10 s, and 60 °C for
30 s. All samples were run in triplicate and levels of
CTFR messages were normalized to GAPDH.
Iodide efflux essay
The assay was performed as previously reported [14].
Briefly, cells were grown on poly-lysine-coated 60-cm
culture dishes and transiently transfected with WT-,
G1208D-, or empty vector using Lipofectamine 2000.
After 48 h, the cells were loaded for 60 min at room
temperature with the loading buffer (136 mM NaI,
137 mM NaCl, 4.5 mM KH2PO4, 1 mM CaCl2, 1 mM
MgCl2, 10 mM glucose, 5 mM HEPES, pH 7.2). Extra-
cellular NaI was washed away thoroughly (5 times) with
the efflux buffer (136 mM NaNO3 replacing 136 mM
NaI in the loading buffer) and cells were equilibrated for
1 min in a final 1-ml aliquot of the efflux buffer. The
first four aliquots were used to establish a stable baseline
in efflux buffer alone. PKA activating agonists cocktail
(10 μM forskolin, 200 μM CPT-cAMP, and 100 μM
IBMX) was added to the efflux buffer and samples were
collected every minute for 6 times in the continued pres-
ence of agonists. The iodide concentration of each sam-
ple was determined using an iodide-sensitive electrode
(Orion Research Inc., Beverly, MA, USA) and the efflux
rates were reported as nano-moles (nmol)/min. After ex-
periments, the cells were lysed and the total protein con-
centrations measured. The maximal iodide efflux rates
of samples were normalized to their total protein con-
centrations of cell lysates.
Statistical analysis
The data were presented as Mean ± S.E.M. Statistical
analyses were performed using Student’s t-test and P
values < 0.05 were considered significant.
Results
Clinical case summary
The patient was identified after positive newborn screen-
ing by the state of Tennessee. The African-American in-
fant was a product of a twin gestation born preterm at
31 weeks. The newborn screening result of this child
was positive, with initial elevated immunoreactive tryp-
sinogen of 148 ng/ml and repeat at 3 weeks of age again
elevated at 123 ng/ml. At 2 months old, the sweat chlor-
ide levels were 51, 45 mmol/L and pancreatic elastase
level was low at 116 μg/g (pancreatic insufficiency).
Based on these lab testing results and poor weight gain,
the child was diagnosed with CF and management was
started, including enzyme replacement therapy. The
child has had poor but steady weight gain. The sweat
chloride levels were 47, 46 mmol/L at 5 months of age
and 54, 48 mmol/L at 29 months of age. Stool elastase
testing was >500 μg/g at 25 months of age, and pancre-
atic enzymes supplementation was stopped. Chest radio-
graph showed normal findings. There have been no
admissions for pulmonary exacerbations, and throat cul-
tures have shown growth of only gram-positive organ-
isms. At 35 months old, the child’s height and weight
were at the 5th and below the 3rd percentile, respect-
ively. DNA sequencing test revealed that the child is
heterozygous for F508del and a missense mutation,
c.3623G > A.
c.3623G > A encoding protein, G1208D-CFTR, has defect
in maturation and shows impairment in channel function
We generated c.3623G > A mutation on a pcDNA3.1-
WT-CFTR background using site-directed mutagenesis.
We tested the expression level and maturation status of
the c.3623G > A encoding protein, p.Gly1208Asp (legacy
name G1208D, which will be used in this manuscript),
using western blotting. HEK293 cells were used to ex-
press the plasmids of G1208D-CFTR, WT-CFTR,
F508del-CFTR, or the vector. As expected, WT-CFTR
was expressed predominantly as a mature form (Band C)
(Fig. 1a), with a maturation efficiency (the percentage of
the mature form CFTR protein (Band C) to total CFTR
protein (Band B plus Band C)) of 90 % (Fig. 1b).
F508del-CFTR was expressed as an immature form
(Band B) and the vector-transfected cells did not express
CFTR protein (Fig. 1a). G1208D-CFTR was expressed in
both mature and immature forms (Fig. 1a), with a mat-
uration efficiency of 57 % (Fig. 1b). The total CFTR pro-
tein expression levels of G1208D and WT were
comparable (Fig. 1c). We also tested the mRNA levels of
G1208D-CFTR and WT-CFTR using real-time PCR and
found their levels were not significantly different (Fig. 1f ).
Our results indicate that G1208D-CFTR has defect in
intracellular processing and trafficking, leading to im-
paired protein maturation.
We next tested the channel function of G1208D-
CFTR in HEK293 cells using iodide efflux assay.
HEK293 cells transfected with WT-CFTR or vector were
used as controls. As shown in Fig. 1d, upon stimulation,
WT-CFTR exhibited a typical CFTR-mediated iodide ef-
flux profile [14] whereas the vector-expressing cells did
not show measureable iodide efflux. Although G1208D-
CFTR showed a response, the magnitude was markedly
smaller compared to WT-CFTR. The maximal iodide ef-
flux rate of G1208D-CFTR was found to be 33 % of that
of WT-CFTR (Fig. 1e). The data demonstrates that the
channel function of G1208D-CFTR is impaired, which
correlates with our finding that the CFTR protein has
defect in maturation.
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G1208D-CFTR can be partially rescued by exposure to low
temperature or using VX-809
Based on the findings that G1208D-CFTR exhibited defect
in processing (Fig. 1), which is a characteristics of the class
II mutations (e.g., F508del), and that F508del-CFTR can
be partially rescued at low temperature or using CFTR
correctors [15], we continued to investigate whether
G1208D-CFTR can be rescued by using a CFTR corrector
VX-809 or exposure to low temperature (28 °C). To test
the temperature effect, HEK293 cells were transfected
with G1208D-CFTR and cultured at 37 °C or 28 °C. Cells
transfected with WT-CFTR or vector was used to facili-
tate the characterization. We found that exposure to low
temperature (28 °C) increased the total CFTR protein level
(1.3-fold) and promoted the maturation of G1208D-CFTR
(a 1.3-fold increase) compared to cultures at 37 °C
(Fig. 2a, b, c). To test the effect of VX-809, HEK293
cells were transfected with G1208D-CFTR and treated
with VX-809 or DMSO (solvent control) and cultured
at 37 °C. We found that VX-809 significantly in-
creased the total CFTR protein level (1.5-fold) of
G1208D-CFTR (Fig. 2d, e) and slightly promoted its
maturation (a 1.1-fold increase). Of note, we did not
find an additive or synergetic effect with the use of
VX-809 and exposure at low temperature.
We then tested whether VX-809 potentiates the
G1208D-CFTR channel function in HEK293 cells using
iodide efflux assay. We found that VX-809 did augment





























































































































































Fig. 1 G1208D-CFTR has defect in protein maturation and shows impaired chloride channel function. a A representative blot showing the
expression level and maturation status of G1208-CFTR, WT-CFTR, F508del-CFTR, or vector transiently expressed in HEK293 cells. Band C denotes a
mature form of CFTR and Band B denotes an immature form of CFTR. b G1208D-CFTR has defect in protein maturation, with a mean maturation
efficiency of 57 %. The data (density of the bands) were quantified from blots as represented in (a) using Image J software and presented as ratio
of Band C to Band B (left panel) and ratio of Band C to total protein (B and C + B and B; right panel). The maturation efficiency was defined as the
ratio of the mature form CFTR (density of Band C) to the total CFTR protein (density of B and C plus Band B). *P <0.05, n = 3. c The total CFTR
protein expression levels of G1208D-CFTR and WT-CFTR are comparable. The densities of the bands were normalized to their loading control,
β-actin, respectively. ns: not significant. n = 3. d Representative iodide efflux traces of G1208D-CFTR, WT-CFTR, or vector transiently expressed in
HEK293 cells. PKA activating agonists (10 μM forskolin, 100 μM IBMX, and 200 μM cpt-cAMP) were added to activate CFTR channel function. e The
maximal iodide efflux rate of G1208D-CFTR is 33 % of that of WT-CFTR. The data were quantified from experiments as represented in (d) and
normalized to the total protein concentrations of cell lysates for each sample, respectively. *P <0.05, n = 5. f The levels of CFTR mRNA are similar
between WT and G1208D. ns: not significant. n = 9
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the channel function of G1208D-CFTR, with a 1.5-fold
increase in the maximal iodide efflux rate compared to
DMSO control (Fig. 2f, g).
Discussion
Newborn screening programs have facilitated the identi-
fication of rare or unique CFTR mutations in popula-
tions such as Africa-Americans where classical CF
presentations are uncommon [16, 17]. Many of these
rare mutations have not been well characterized with re-
gard to CFTR channel function and there is a risk that
mutations that potentially respond to CFTR-modifying
therapies may not be identified in these populations.
Our biochemical findings demonstrate that G1208D-
CFTR has a moderate processing defect, characterized
by features of impaired CFTR protein maturation and
channel function, as well as sensitivity to temperature
and responsiveness to correction with VX-809. Although
it is well known that variables in genetic background
(e.g. modifier genes) and environment factors also affect
CF disease manifestations [18], our finding that
G1208D-CFTR has residual CFTR function (33 % of



















































































































































































Fig. 2 G1208D-CFTR can be partially rescued by exposure to low temperature or using VX-809. a A representative blot showing the expression
level and maturation status of G1208D-CFTR in HEK293 cells cultured at normal condition (37 °C) or at a low temperature (28 °C). WT-CFTR- and
vector-transfected HEK293 cells were cultured at 37 °C and used as controls. b Exposure to low temperature (28 °C) promoted the maturation
efficiency (1.3-fold) of G1208D-CFTR. The data were quantified from blots as represented in (a) using Image J software. *P <0.05, n = 3. c Exposure
to low temperature (28 °C) increased the total CFTR protein level of G1208D (1.3-fold). The data were quantified from blots as represented in (a)
using Image J software and normalized to their loading control, β-actin, respectively. *P <0.05, n = 3. d A representative blot showing the
expression level and maturation status of G1208D-CFTR in HEK293 cells treated with VX-809 (5 μM) or DMSO (solvent control for VX-809).
WT-CFTR- and vector-transfected HEK293 cells were used as controls. e VX-809 increased the total CFTR protein level of G1208D-CFTR (1.5-fold).
The data were quantified from blots as represented in (d) using Image J software and normalized to their loading control, β-actin, respectively.
*P <0.05, n = 3. f Representative iodide efflux traces of G1208D-CFTR in HEK-293 cells treated with VX-809 (5 μM) or DMSO. PKA activating agonists
(10 μM forskolin, 100 μM IBMX, and 200 μM cpt-cAMP) were used to activate CFTR channel function. g The maximal iodide efflux rate of G1208D-
CFTR increased 1.5-fold with VX-809 treatment compared to DMSO-treated controls. The data were quantified from experiments as represented
in (f) and normalized to the total protein concentrations of cell lysates for each sample, respectively. *P <0.05, n = 9–11
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phenotype in this patient, with preserved pancreatic
function and intermediate sweat chloride levels, when
paired with a classical CFTR mutation like F508del.
Our patient is still too young to evaluate the effect of
the mutation on lung damage but it has been known
that patients with residual CFTR channel function can
still develop bronchiectasis with chronic sino-pulmonary
infections and other CF-related diseases (e.g., recurrent
pancreatitis, CF-related diabetes, male infertility) when
they age [8]. Given that the two mutations this patient
has, F508del and c.3623G > A, are both responsive to
VX-809, we speculate that VX-809 and similar CFTR
modulators could be beneficial for his therapy.
Conclusions
We report the clinical features of a pediatric CF patient
heterozygous for F508del and a novel missense
c.3623G > A mutation. We characterized c.3623G > A
mutation at the molecular level using cell culture models
and found that the mutant protein has a moderate pro-
cessing defect and an impaired channel function, which
correlates with the mild disease phenotype present in
this patient. Our study suggests that c.3623G > A muta-
tion is a mild CF-causing mutation. We also found that
the mutant protein can be partially rescued by using a
CFTR corrector VX-809 or exposed at a low
temperature. Our findings expand our knowledge of rare
CFTR mutations, demonstrate that VX-809 restores
function to other rare mutations in addition to F508del,
and may have clinical implications for possible thera-
peutic interventions for this and other patients with
c.3623G > A mutation.
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